Novartis Files For Approval Of Rasilez In Japan
This article was originally published in PharmAsia News
Executive Summary
Novartis Pharma of Japan has applied for approval of the high blood pressure drug Rasilez (aliskiren). Aliskiren is the first in a new class of medicine that works by inhibiting renin (an enzyme secreted by the kidney). Aliskirenhas been approved by the U.S. FDA and is sold under the name Tektuna in the U.S. and as Rasilez in Europe. (Click here for more - Japanese language
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.